Table 1.
Baseline characteristics
| Intermediate insulin isophane | Long-acting insulin glargine | Biphasic pre-mixed insulin | |
|---|---|---|---|
| n | 273 | 24 | 42 |
| Sex, n (%) | |||
| Male | 139 (50.9) | 15 (62.5) | 21 (50.0) |
| Female | 134 (49.1) | 9 (37.5) | 21 (50.0) |
| Mean (SEM) weight (kg) | 91.4 (25.3) | 86.0 (21.5) | 93.4 (36.0) |
| BMI (kg/m2) | 31.6 | 31.5 | 32.3 |
| Mean (SEM) age (years) | 55.7 (13.9) | 59.2 (16.5) | 56.7 (11.4) |
| Mean (SEM) duration of diabetes (years) | 10.6 (6.7) | 9.2 (6.6) | 12.0 (9.8) |
| Poor glycemic controla, n (%) | 114 (41.8) | 11 (45.8) | 21 (50.0) |
| Median insulin dose at initiation (units/kg) | 0.2 | 0.2 | 0.3 |
| Oral hypoglycemic agents, n (%) | |||
| Metformin | 210 (76.9) | 16 (66.7) | 33 (78.6) |
| Sulfonylurea | 186 (68.1) | 17 (70.8) | 13 (31.0) |
| Other | 10 (3.7) | 3 (12.5) | 1 (2.4) |
BMI body mass index, SEM standard error of the mean
a p = 0.013 vs. intermediate-acting insulin isophane
b p < 0.05 vs. intermediate-acting insulin isophane